La cadena de opciones muestra datos clave de las opciones de acciones de CNS Pharma a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para CNS Pharma..

CNS Pharma (NASDAQ:CNSP) Bolsa, Cadena de Opciones

CNS Pharmaceuticals

CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

CNS Pharmaceuticals Inc

U.S. stocks settled lower on Friday, with the Dow Jones index falling more than 300 points during the session.
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst&#8217;s opinion to trust.
Benzinga&#8217;s Analyst Ratings API is a collection of the highest-quality stock ratings curated by the Benzinga news desk via direct partnerships with major sell-side banks. Benzinga displays overnight ratings changes on a daily basis three hours prior to the U.S. equity market opening. Data specialists at investment dashboard provider Toggle.ai recently uncovered that the analyst insights Benzinga Pro subscribers and Benzinga readers regularly receive can successfully be used as trading indicators to outperform the stock market.
Top Analyst Picks: Fortunately, any Benzinga reader can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. One of the ways traders can sort through Benzinga&#8217;s extensive database of analyst ratings is by analyst accuracy. Here&#8217;s a look at the most recent stock picks from each of the five most accurate Wall Street analysts, according to Benzinga <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock</a> Ratings.
Analyst: Trevor Walsh
<ul>
<li>Analyst Firm: JMP Securities</li>
<li>Ratings Accuracy: 90%</li>
<li>Latest Rating: Maintained a Market Outperform rating on Planet Labs PBC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) and raised the price target from $4.5 to $6.5 on Jan. 30. This analyst sees around 11% upside in the stock.</li>
<li>Recent News: On Jan. 29, Planet signed a $230 million commercial agreement for Pelican Satellites.</li>
</ul>
Analyst: Zachary Fadem
<ul>
<li>Analyst Firm: Wells Fargo</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained an Equal-Weight rating on Brinker International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) and increased the price target from $145 to $175 on Jan. 30. This analyst sees a 3% decline in the stock.</li>
<li>Recent News: On Jan. 29, Brinker International reported better-than-expected second-quarter results.</li>
</ul>
Analyst: Alexander Paris 
<ul>
<li>Analyst Firm: Barrington Research</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained an Outperform rating on Adtalem Global Education Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATGE#NYSE">ATGE</a>) and increased price target from $115 to $120 on Jan. 31. This analyst sees around 12% upside in the stock.</li>
<li>Recent News: On Jan. 30, Adtalem Global Education reported better-than-expected second-quarter financial results and raised its FY25 guidance.</li>
</ul>
Analyst: Rob Owens
<ul>
<li>Analyst Firm: Piper Sandler</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained an Overweight rating on Atlassian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) and raised the price target from $310 to $365 on Jan. 31. This analyst sees around 21% surge in the stock.</li>
<li>Recent News: On Jan. 30, Atlassian reported better-than-expected second-quarter financial results.</li>
</ul>
Analyst: Andres Sheppard
<ul>
<li>Analyst Firm: Cantor Fitzgerald</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Maintained a Neutral rating on Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and boosted the price target from $365 to $425 on Jan. 30. This analyst sees more than 8% upside in the stock.</li>
<li>Recent News: Tesla has started production of its refreshed Model Y across its four factories around the globe including its gigafactory in Texas, the company said in a post on X, formerly Twitter.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43390127/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

Adtalem Global Education Inc. Common Stock

ATGE

TEAM

TSLA

This Analyst With 85% Accuracy Rate Sees More Than 8% Upside In Tesla - Here Are 5 Stock Picks For January From Wall Street's Most Accurate Analysts

We live in a world where facts dissolve into fiction faster than ever. A new plague of deception—fueled not by biology but by algorithms—is spreading globally. Call it the "infodemic," a storm of AI-generated lies, hyper-realistic deepfakes, and synthetic documents, many originating from Chinese tech labs. As those AI tools become increasingly sophisticated in deception, they can corrode trust in more than one way, posing risks to democracy, art, our finances and even love. With elections in over 50 nations looming by 2025, the stakes are existential.
Open-source AI's dark side
Currently, platforms like Midjourney and <a href="https://www.nytimes.com/2024/05/07/technology/openai-deepfake-detector.html">OpenAI's tools </a>have put safeguards in place to prevent misuse, ensuring that content like deepfakes stay out of circulation online as much as possible. However, open-source models can be fine-tuned and weaponized by those with bad intent, empowering scammers to spread disinformation, deepfakes and fraud.&nbsp;
When AI steals the spotlight
The cases of AI scams are probably the most publicized in the entertainment industry. Hollywood in particular now battles synthetic impostors on a regular basis. Public figures must contend with the potential for their likeness to be ripped off for someone else's gain, with deepfakes infiltrating platforms like X on a daily basis, whether it's to offer fake brand endorsements or to generate scandals. This ease of creation, coupled with the vast reach of social media platforms, creates a potent combination for disseminating misinformation and scams.
But not everyone sees this as a loss. Take Grimes, who leases her voice to AI clones for royalties—a "deepfake-as-a-service" model. This begs a grim question: Do artists have to auction their identities to stay relevant?&nbsp;
<h3 class="wp-block-heading">Algorithmic love lies</h3>
Famous artists aside, none of us are safe, particularly when it comes to finding real love. Forget poorly photoshopped profiles—today's catfishing involves AI-generated personas so convincing they mimic celebrities.
With Chinese platforms like DeepSeek, with reasoning capabilities equivalent to ChatGPT, and open source generators like Flux giving users an ability to generate deepfakes with remarkable accuracy, it becomes increasingly challenging for even the most digitally savvy individuals to see through a lie.&nbsp;
According to the FBI, last year 19,000 Americans fell victim to romance scams, losing $1.3 billion. Solutions like watermarking AI content exist, but without global enforcement, fraudsters thrive in the gaps.
How many more Brad Pitt deepfake scams do we need to live through before we do something about it? Platforms <a href="https://venturebeat.com/games/ai-or-not-raises-5m-to-stop-ai-fraud-deepfakes-and-misinformation/">detecting AI</a> across videos, images and texts already help millions of people verify AI generated content, helping them save their money, and even marriages in this case.&nbsp;
<h3 class="wp-block-heading">Beijing's "document mills"</h3>
Another area requiring fast innovation in the realm of fraud detection is KYC scams. Open-source AI models, fine-tuned well, produce fake passports and contracts indistinguishable from real ones. These tools slip past banks' KYC checks, forcing financial institutions into an expensive arms race. Biometric-based fraud has gone up 40% in 2024 and is showing no signs of slowing down. HSBC now uses AI "detectives" to hunt forged documents—a Band-Aid on a bullet wound.
We need to start a discussion about how banks can create an actual filter protecting their customers from falling prey to the next KYC scam.&nbsp;
<h3 class="wp-block-heading">Synthetic news and political manipulation</h3>
Finally, even platforms that used to signify public trust are not safe anymore. Last year, AI impersonated the BBC, publishing fabricated stories about politicians. The fallout wasn't just embarrassment—it was a warning. In 2025, as billions vote globally, such scams need to be taken more seriously. The attack won't come from hackers, but from code written in Shenzhen or Shanghai.
This is already a reality in China. For example, a disinformation <a href="https://jamestown.org/program/deepfakes-with-chinese-characteristics-prc-influence-operations-in-2024/">campaign </a>aimed at DPP presidential candidate Lai Ching-Te was flooded with deepfake content. Manipulated videos, using synthesized versions of Lai&#8217;s voice, misleadingly showed him endorsing a coalition between the KMT and TPP, and inaccurately depicted him discussing DPP scandals. While sharing content across platforms is a staple in influence operations, Beijing&#8217;s ability to shape the information landscape, particularly on Chinese social media, grows with each byte of data it gathers. This data empowers them to craft disinformation with precision, aimed at individuals based on their unique beliefs.&nbsp;
<h3 class="wp-block-heading">Fighting back</h3>
In the context of sustained US-China tensions, information warfare plays an increasingly vital role in shaping perceptions and influencing outcomes. This necessitates internet users to start scrutinizing what they see online in a much greater detail, building a new habit of scanning content for synthetic fingerprints, merging human skepticism with machine precision. At the other end of the spectrum, organizations need to step up their game in how they protect their users and customers against AI fraud. Social platforms should authenticate users, and banks must start investigating API integrations for creating additional security layers preventing KYC failures.
While Western regulators ponder changes at a snail's pace, making very little progress in the past 10 years, Chinese AI firms export tools that turbocharge disinformation in a way that makes it impossible to discern what's real, and the time to act is now.
The infodemic feeds on indifference. Without action, we'll inhabit a world where authenticity is extinct—a place where every video, voice, or contract could be a lie. The antidote? Licensing models to credit creators, detection tech to expose fakes, and ethical guardrails for AI platforms. By 2026, we'll learn whether we are able to tame this crisis—or if&nbsp; it will consume us.

Tech

China-Borne Silent Infodemic No One is Talking About

Telsey Advisory Group analyst Dana Telsey maintains Tapestry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) with a Outperform and raises the price target from $74 to $83.

Telsey Advisory Group Maintains Outperform on Tapestry, Raises Price Target to $83

Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) is reportedly gearing up to unveil five new products in March, including the iPhone SE 4, M4 MacBook Air, and a new iPad Air.
What Happened: The iPhone SE 4, Apple&#8217;s most affordable iPhone, is expected to undergo a significant upgrade, <a href="https://9to5mac.com/2025/02/02/five-apple-products-coming-soon-next-month-spring/">reported</a> 9to5Mac on Monday. The upcoming model is expected to have a design similar to the iPhone 14, incorporate an in-house modem, and include a USB-C port. It might also be rebranded as the "iPhone 16E."
Apple&#8217;s budget iPad is slated for its first update in more than two years, featuring Apple Intelligence support and the new A17 Pro chip.
SEE ALSO: <a href="https://www.benzinga.com/25/01/43294364/apple-surprises-iphone-users-by-teaming-up-with-spacex-and-t-mobile-to-bring-starlink-satellite-texting-heres-what-you-need-to-know-about-the-new-feature">Apple Surprises Users With Starlink Beta, Teams Up With Elon Musk&#8217;s SpaceX And T-Mobile To Bring Satellite Texting For iPhone Users In iOS 18.3</a>
The MacBook Air is set to receive a chip upgrade to the M4, while the iPad Air is anticipated to feature an M3 chip along with a new Magic Keyboard.
Apple&#8217;s first smart home device with a display is set to launch next month, incorporating Apple Intelligence support. Furthermore, a refreshed AirTag model featuring an upgraded ultra-wideband chipset is anticipated to be released.
Why It Matters: The new lineup of Apple products is expected to be unveiled at the company&#8217;s spring product launch event in March, as <a href="https://www.macrumors.com/guide/apple-event/">reported</a> by MacRumors. The event is anticipated to showcase a range of new devices, including the iPhone SE 4, the M4 MacBook Air, and the new iPad Air.
These new product releases are expected to have a significant impact on Apple&#8217;s performance in the market, especially considering the company&#8217;s recent <a href="https://www.business-standard.com/technology/tech-news/apple-s-2025-lineup-iphone-se-4-m4-macbook-air-and-more-expected-soon-125020300727_1.html">focus on affordability and accessibility</a>.
<ul>
<li>READ NEXT: <a href="https://www.benzinga.com/tech/25/02/43424187/apples-struggles-in-ai-and-ar-indicate-a-loss-in-product-edge">Apple&#8217;s Struggles in AI and AR Indicate a Loss in Product Edge</a></li>
</ul>
This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Image via Shutterstock

AAPL

Apple's Spring 2025 Lineup: iPhone SE 4, M4 Macbook Air And More Expected Soon

Telsey Advisory Group analyst Joseph Feldman maintains Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Outperform and maintains $1100 price target.

COST

Telsey Advisory Group Maintains Outperform on Costco Wholesale, Maintains $1100 Price Target

Murata Manufacturing (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRAAY#OTC">MRAAY</a>) reported quarterly earnings of $0.25 per share. This is a 177.78 percent increase over earnings of $0.09 per share from the same period last year. The company reported $2.94 billion in sales this quarter. This is a 1.14 percent decrease over sales of $2.97 billion the same period last year.

Earnings

MRAAY

Murata Manufacturing Q3 EPS $0.25 Up From $0.09 YoY, Sales $2.94B Down From $2.97B YoY

Nvidia Corp.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) GeForce RTX 5090 and 5080 graphics <a href="https://in.benzinga.com/25/01/43378899/nvidia-rtx-5090-and-5080-sell-out-instantlyscalpers-jack-up-prices-to-6000-as-gamers-face-paper-launch-frustration">cards have sold out</a> almost immediately after their release. However, gaming enthusiasts can still acquire these powerful GPUs through high-end prebuilt gaming PCs.
What Happened: The GeForce RTX 5090 and 5080 graphics cards are nearly impossible to find due to limited availability. As a result, enthusiasts are turning to prebuilt gaming PCs to get their hands on these coveted GPUs.
These prebuilt systems, available on platforms like Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), come at a premium price.
For instance, a Sentinel gaming desktop featuring the RTX 5090 is priced at $5,599.99. It includes an Intel Core i9-14900KF processor, 64GB of DDR5 memory, and a 2TB SSD, among other high-end components.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/25/01/43377131/tim-cook-wont-say-how-apple-plans-to-handle-trumps-tariff-policies-but-heres-whats-at-stake-for-the-iphone-maker" target="_blank" rel="noreferrer noopener">Tim Cook Won't Say How Apple Plans To Handle Trump's Tariff Policies — But Here's What's At Stake For The iPhone Maker</a>
For those considering the RTX 5080, prices are somewhat lower. A Skytech Azure gaming desktop with the RTX 5080 is listed at $2,699.99. This setup includes an AMD Ryzen 7 9800X3D processor, 32GB of DDR5 memory, and a 2TB SSD.
While these systems are not discounted, they offer a way to access NVIDIA&#8217;s latest Blackwell GPU architecture without waiting for standalone cards to become available.
However, potential buyers should be prepared to pay a significant premium for immediate access.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: Previously, it was reported that the scarcity of RTX 5090 and 5080 graphics cards has led to scalpers inflating prices to as much as $6,000, further exacerbating the frustration among gamers.
Nvidia is set to announce its fourth-quarter earnings on Feb. 26. In the last quarter, the company <a href="https://www.benzinga.com/news/earnings/24/11/42099904/nvidia-beats-q3-revenue-eps-estimates-supply-constraints-ding-stock-huang-says-age-of-ai-is-in-full-steam">reported $35.1 billion in revenue</a>, reflecting a 94% year-over-year increase and exceeding Wall Street&#8217;s forecast of $33.12 billion.
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/43221770/apples-ipad-turns-15-today-heres-a-throwback-to-when-steve-jobs-explained-called-it-the-third-category-after-phones-and-notebooks" target="_blank" rel="noreferrer noopener">Apple&#8217;s iPad Turns 15 Today: Here&#8217;s A Throwback To When Steve Jobs Explained Called It The ‘Third Category&#8217; After Phones And Notebooks</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

AMZN

NVDA

Nvidia's RTX 5090 And 5080 Are Sold Out, But You Can Still Get One With These High-End Prebuilt Gaming PCs

Glo Fiber, powered by&nbsp;Shenandoah Telecommunications Company ("Shentel") (NASDAQ:<a href="https://www.benzinga.com/stock/SHEN#NASDAQ">SHEN</a>),&nbsp;announced that construction of their Glo Fiber 100% fiber optic broadband service is underway in Lancaster, Ohio. Glo Fiber's future-proof, reliable high-speed internet service is already available to more than 4,000 homes and businesses in Lancaster, and construction will expand service to approximately 10,000 additional homes and businesses in the city. Construction began in the summer of 2024 with expected completion planned for the second half of 2025.&nbsp;

SHEN

Shenandoah Telecommunications' Glo Fiber Expands High-Speed Internet in Lancaster, Ohio

Smart Share Global Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EM#NASDAQ">EM</a>) ("Energy Monster" or the "Company"), a consumer tech company providing mobile device charging service, today announced that it received a notification letter (the "Compliance Notification") from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"), dated January 31, 2025, notifying the Company that it has regained compliance with the requirement of minimum bid price of US$1.00 per share set forth under Nasdaq Listing Rule 5550(a)(2).
As announced on August 9, 2024, the Company received a letter from Nasdaq indicating that it was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the closing bid price of its American Depositary Shares (the "ADSs") had been below US$1.00 per ADS for the previous 30 consecutive business days. The Company was provided with a compliance period of 180 calendar days, or until February 3, 2025, to regain compliance with the minimum bid price requirement.

Government

Regulations

Smart Share Global Avoids Nasdaq Delisting, Stock Price Back Above $1

Triumph Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGI#NYSE">TGI</a>) ("TRIUMPH" or the "Company") today announced that it has entered into a definitive agreement under which affiliates of growth-focused private equity firms Warburg Pincus and Berkshire Partners will acquire TRIUMPH through a newly formed entity for a total enterprise value of approximately $3 billion. Upon completion of the transaction, TRIUMPH will become a privately held Company, jointly controlled by Warburg Pincus and Berkshire Partners.
Under the terms of the agreement, TRIUMPH shareholders will receive $26.00 per share in cash. The purchase price represents a premium of approximately 123% over the Company's unaffected closing stock price and a premium of approximately 58% over the volume weighted average price (VWAP) of TRIUMPH common stock for the 90 days prior to January 31, 2025.

Triumph Group to Go Private in $3B Deal Backed by Private Equity Firms Warburg Pincus and Berkshire Partners, Implying A 123% Premium

Macro Economic Events

Econ #s

Economics

Eurozone Consumer Price Index (YoY) Preliminary For January 2.5% Vs. 2.4% Est.; 2.4% Prior

Eurozone Consumer Price Index (MoM) Preliminary For January -0.3% Vs. 0.4% Prior

Eurozone Core Consumer Price Index (YoY) Preliminary For January 2.7% Vs. 2.6% Est.; 2.7% Prior

Biotech

Large Cap

Health Care

General

AstraZeneca's Imfinzi (Durvalumab) Has Been Recommended For Approval In The European Union For Limited-stage Small Cell Lung Cancer Whose Disease Has Not Progressed Following Platinum-Based Chemoradiation Therapy

U.K. Manufacturing Purchasing Managers Index For January 48.3 Vs. 48.2 Est.; 47.0 Prior

Eurozone Manufacturing Purchasing Managers Index For January 46.6 Vs. 46.1 Est.; 45.1 Prior

Raymond James analyst Andrew Cooper downgrades Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) from Outperform to Market Perform.

Downgrades

Raymond James Downgrades Danaher to Market Perform

Germany Manufacturing Purchasing Managers Index For January 45.0 Vs. 44.1 Est.; 42.5 Prior

France Manufacturing Purchasing Managers Index For January 45.0 Vs. 45.3 Est.; 41.9 Prior

Raymond James analyst Brian Gesuale upgrades Booz Allen Hamilton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) from Market Perform to Outperform and announces $150 price target.

Upgrades

Raymond James Upgrades Booz Allen Hamilton to Outperform, Announces $150 Price Target

"Our team has made nothing short of transformational advancements throughout 2024. Fundamentally, the Company has never been stronger, and we belie...

CNS Pharmaceuticals reports Q3 EPS (25c) vs. ($54.14) last year

As of September 30, 2024, the Company had cash of approximately $7.0 million. Subsequent to the quarter end, the Company closed a $3.0 million regi...

CNS Pharmaceuticals sees cash runway through 2Q25

CNS Pharmaceuticals reports Q3 results

CNS Pharmaceuticals (CNSP) announced the presentation of updated results from the on-going potentially pivotal study evaluating Berubicin, the Comp...

CNS Pharmaceuticals presents update from ongoing study of berubicin

Catalyst Watch:  Goldman Sachs finance conference; Adobe, CostCo earnings

CNS Pharmaceuticals ( ($CNSP) ) has provided an announcement. CNS Pharmaceuticals announced a virtual analyst and investor day to discuss its lead ...

CNS Pharmaceuticals Hosts Virtual Analyst and Investor Day

CNS Pharmaceuticals ( ($CNSP) ) has provided an update. CNS Pharmaceuticals has completed enrollment in a pivotal clinical trial for Berubicin, a p...

CNS Pharmaceuticals Advances Berubicin and TPI 287 Projects

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Puma...

Biotech Alert: Searches spiking for these stocks today

Alliance Global Partners initiated coverage of CNS Pharmaceuticals (CNSP) with a Buy rating and $4 price target CNS is a clinical-stage pharmaceuti...

CNS Pharmaceuticals initiated with a Buy at Alliance Global Partners

In a report released today, James Molloy from Alliance Global Partners initiated coverage with a Buy rating on CNS Pharmaceuticals (CNSP – Research...

Alliance Global Partners Initiates a Buy Rating on CNS Pharmaceuticals (CNSP)

ADBE

ADSK

AKAM

AVGO

CIEN

CLRB

CNSP

COIN

CSCO

CSGP

DGLY

ETSY

GDDY

HMBL

IMPP

LGND

MTCH

NTNX

NVAX

OLLI

ORCL

ORIS

PBYI

PLAY

PSNY

PZZA

RILY

RVNC

SEAT

SHAK

SMAR

SPIR

TTAN

TWLO

UBER

UNFI

ZYME

Screenshot 2024-02-26 at 8.44.39 PM

GBM, One Of The Deadliest Cancers, Could Have New Hope With Novel Drug

Events

Press Releases

CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC

CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment

CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Stocks Under Ten Cents to Watch in October 2024 CNSP, QLGN, AKTS, CBDW, RJDG

CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

Comments

CNS Pharma

CNS Pharma (CNSP) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL